This inventor holds 5 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Teva Biopharmaceuticals USA, Inc.. Active years: 2012-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Rockville, MD (US) (2012 - 2014)
- Germantown, MD (US) (2013 - 2016)
Company Filing History:
Years Active: 2012-2016
Title: **Innovator Spotlight: Palanisamy Kanakaraj**
Introduction
Palanisamy Kanakaraj is a prominent inventor based in Germantown, MD, who has made significant contributions to the field of biopharmaceuticals. With a total of five patents to his name, Kanakaraj's work has been instrumental in the development of innovative treatments aimed at addressing complex medical conditions.
Latest Patents
Among his latest contributions, Kanakaraj has developed humanized antibodies against TL1A, specifically targeting TNF superfamily member 15 (TNFSF15), also referred to as TL1A. These humanized antibodies exhibit the potential to act as antagonists and can be utilized to treat or diagnose various conditions associated with TL1A function. The disclosed methods provide insights into creating and employing these anti-TL1A antibodies, demonstrating Kanakaraj's dedication to advancing therapeutic options in the medical field.
Career Highlights
Palanisamy Kanakaraj is currently employed at Teva Biopharmaceuticals USA, Inc., where he continues to push the boundaries of biopharmaceutical innovation. His work focuses on creating novel therapies that leverage cutting-edge scientific developments to improve patient outcomes.
Collaborations
Throughout his career, Kanakaraj has collaborated with several esteemed colleagues, including Rodger G. Smith and Viktor Roschke. These partnerships enhance the collaborative efforts within the scientific community and aid in driving forward the research and development of new biomedical therapies.
Conclusion
In summary, Palanisamy Kanakaraj is a distinguished inventor whose work in developing humanized antibodies offers promising avenues for treating and diagnosing conditions related to TL1A function. His contributions at Teva Biopharmaceuticals USA, Inc. and collaborations with fellow innovators underscore his vital role in the advancement of biopharmaceuticals. Through his continued efforts, Kanakaraj exemplifies the spirit of innovation that drives progress in the healthcare sector.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile